Inovio extends Series A Warrant expiration to March 31, 2026

INOVIO PHARMACEUTICALS, INC.

Amendment extends expiration of Series A Warrants (up to 13,564,268 shares) from Jan 28, 2026 to March 31, 2026.
Warrants issued in July 2025 public offering; exercise price $1.75/share (pre-funded at $0.001).
Original expiration was 30 days after FDA BLA acceptance for INO-3107; extension provides additional exercise window.
All other warrant terms remain unchanged.

item 1.01 item 3.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

INOVIO PHARMACEUTICALS, INC. amended Series A Warrants (effective 2026-01-27).

Action: amendment
Effective: 2026-01-27

Exact text from the filing

On January 27, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) amended each of its outstanding Series A warrants issued on July 7, 2025 (the “Series A Warrants”) to extend the expiration date

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-024431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.